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Abstract
Plasmodium vivax, the second most prevalent of the human malaria parasites, is estimated to affect 75 million people
annually. It is very rare, however, in west and central Africa, due to the high prevalence of the Duffy negative phenotype in
the human population. Due to its rarity in Africa, previous studies on the phylogeny of world-wide P. vivax have suffered
from insufficient samples of African parasites. Here we compare the mitochondrial sequence diversity of parasites from
Africa with those from other areas of the world, in order to investigate the origin of present-day African P. vivax.
Mitochondrial genome sequencing revealed relatively little polymorphism within the African population compared to
parasites from the rest of the world. This, combined with sequence similarity with parasites from India, suggests that the
present day African P. vivax population in humans may have been introduced relatively recently from the Indian
subcontinent. Haplotype network analysis also raises the possibility that parasites currently found in Africa and South
America may be the closest extant relatives of the ancestors of the current world population. Lines of evidence are adduced
that this ancestral population may be from an ancient stock of P. vivax in Africa.
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Introduction
Plasmodium vivax, responsible for many tens of million cases of
malaria globally every year, is the second most abundant malaria
parasite of humans after Plasmodium falciparum [1]. It has the
broadest geographic range of the five malaria parasites infective to
man, but appears to be almost completely absent in humans from
large parts of western and central Africa, where P. falciparum is at
its most abundant [2]. This situation is attributed to the high
prevalence of the Duffy negative blood condition in the local
human populations of this area [3].
The Duffy antigen/receptor for chemokines (DARC) is a
transmembrane glycoprotein that is present on epithelial cells [4],
endothelial cells [5], and erythrocytes. It is utilised by P. vivax
parasites as a receptor for attachment to the erythrocyte surface.
One of the alleles of the gene that encodes the DARC protein,
FY*Bnull, carries a single nucleotide mutation which impairs
promoter activity by disrupting a binding site for the h-GATA-1
erythroid transcription factor [6]. This results in the loss of DARC
expression on erythrocytes, but does not affect expression in
epithelial or endothelial cells. Individuals who are homozygous for
this allele thus express no DARC protein on the erythrocyte
surface and so are completely protected from the erythrocytic
cycle of P. vivax.
The Duffy negative phenotype occurs in over 95% of the
human population indigenous to west and central Africa, but is
extremely rare outside of Africa and the Arabian peninsula [7]. It
appears that some form of ‘‘selective sweep’’ event (possibly
involving two distinct haplotypes) occurred in the African human
population which selected for this mutation, as heterozygosity
around the FY*Bnull allele is low compared to elsewhere on the
genome [8]. Population genetics analysis revealed that this
selection probably occurred between 6,500 and 97,200 years ago
(95% confidence interval) [8]. Given the strong association
between the parasite and DARC, it has long been proposed that
P. vivax was the causative agent for the near fixation of the Duffy
negative condition in the African population. Other possible
explanations include selection by other pathogens (trans-mem-
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brane receptors on the surface of blood cells are obvious targets for
cell-invasion [9]), or the hitchhiking of the FY*Bnull allele during
selection for a closely linked gene [8].
P. vivax is part of a clade of parasites that predominantly infect
catarrhine monkeys in South East Asia, and is generally assumed
to have become a parasite of humans via a host switch event. It has
been estimated that P. vivax diverged from Plasmodium cynomolgi
(possibly its most closely related sister-species) between 1.17 and
1.60 million years ago, and that the most recent common ancestor
of all extant P. vivax parasites lived around 400,000 years ago [10];
however, it should be noted that neither of these dates necessarily
corresponds to the time at which P. vivax became parasitic on
humans (i.e. the time of the host-switch event). This relatedness to
parasites infecting monkeys in Southeast Asia, has led many to
speculate that P. vivax emerged as a human parasite in this area.
However, as the range of the cattarhine monkeys may have
extended over large parts of Eurasia at the time of the host-switch,
we must consider that this event may have occurred anywhere on
these continents where host ranges overlapped [11]. When and
where its ancestral line arose and how P. vivax spread from its point
of origin to its present day distribution, are difficult to ascertain,
and remains the subject of much speculation and controversy. A
analysis by Mu et al, based on mitochondrial genome sequences
from 176 P. vivax isolates from a wide geographic range, was
interpreted to suggest that P. vivax originated in Southeast Asia and
spread westwards through India and into Africa [12]. This
interpretation was supported by Cornejo and Escalante [10] who
combined these data with a further 105 mitochondrial sequences
from Jongwutiwes et al [13]. In all three studies, parasites from
Southeast Asia were found to be the most polymorphic, followed
by those from Melanesia, the Indian sub-continent, Africa and
South America respectively. If we assume that the population
showing the highest degree of polymorphism is the most ancient,
then these data suggest a simple east-to-west invasion by P. vivax
from a source population in Southeast Asia. However, currently
‘‘most ancient’’ is not the same as ‘‘original’’; any assumption to
this effect overlooks the complexity of what may have happened
between the time and location of an ‘‘origin’’, in the sense of
divergence of a line of organisms from a source population, and
the possibly later appearance of the ‘‘most ancient’’ extant
population of organisms from that line of descent. Both migration
and lineage extinction (bottlenecking) can obscure the geograph-
ical origin of the ancestral haplotype.
In an attempt to gain further insight into this question, we apply
a population genetics analysis to P. vivax isolates from continental
Africa, Madagascar and Turkey. We have collected 23 isolates of
African/Malagasy P. vivax from Sa˜o Tome´ (n = 1), Tanzania
(n = 1), Angola (n = 1), Rwanda (n = 1), Niger (n = 1) and
Madagascar (n = 18), and 10 isolates from Turkey, from which
the mitochondrial genome was sequenced. These sequences were
used to construct a haplotype network for African P. vivax. We also
combine these sequence data with previously reported sequences
[12,13] in order to investigate how the present day African P. vivax
population relates to parasites from the rest of the world.
Materials and Methods
Samples from Turkey
A total of 10 blood samples were collected from patients with
patent P. vivax malaria at several National Malaria Control
Centers within Siverek in Sanliurfa province during the peak
season (July to December) of 2004, as previously described [14].
Patent infection was diagnosed by staining of the blood samples
with 10% Giemsa’s solution and examination with standard light
microscopy. All samples were collected after informed consent was
obtained from patients or their parents. Sampling authorization
was obtained from the Turkish Ministry of Health Sanliurfa
Bureau, Sanliurfa, Turkey, and ethical approval was obtained
from the Research Institute for Microbial Diseases, Osaka
University, Osaka, Japan.
Samples from Madagascar
Twenty Samples were collected from symptomatic malaria
patients from seven locations (Ampasimpotsy, Saharevo, Antana-
narivo, Ankazobe, Taolagnaro, Antananarivo and Sainte Marie),
diagnosed with P. vivax by microscopy between 1998 and 2005. P.
vivax was confirmed in 18 of these samples by PCR diagnosis. All
samples were collected after written informed consent was
obtained from patients or their parents. Administrative authori-
zations and ethical clearance were provided by the Ministry of
Health and National Ethic Committee, Antananarivo, Madagas-
car. Seven isolates contained dual infections of distinct mitochon-
drial genotypes, identified by i) a difference in the repeat length of
an internal T-repeat microsatellite marker but no SNPs (six
samples), or by ii) overlapping peaks at a single nucleotide (one
sample), yielding a total of 25 genotypes in 18 isolates. The
internal T-repeat microsatellite marker was subsequently removed
from all samples prior to phylogenetic analysis.
Additional African P. vivax samples
Samples of African P. vivax were acquired from Angola, Sa˜o
Tome´, Rwanda, Niger and Tanzania. The Angolan sample came
from an Angolan traveler reporting to the Central Laboratory of
Institute of Tropical Medicine and Hygiene of Lisbon in 2003.
Plasmodium vivax was diagnosed by microscopy and PCR and blood
samples were stored in liquid nitrogen before parasite DNA
extraction Ethical clearance for the use of this sample was given by
the Ethical Committees of Instituto de Higiene e Medicina
Tropical, Lisbon, Portugal, according to EU guidance. The Sa˜o
Tome´an sample was collected from the Centro Policlı´nico de
Sau´de de A´gua Grande, in the city of Sa˜o Tome´ in 2004, following
ethical approval from the Ministry of Health of the Democratic
Republic of Sa˜o Tome´ and Prı´ncipe. Rwandan and Nigerian
samples were acquired from Japanese travelers reporting to the
International Medical Centre Hospital, Tokyo in 2005 and 2006
respectively. Both patients were diagnosed with P. vivax by PCR
and microscopy, and blood samples were stored at 280uC before
parasite DNA extraction was performed using a QIAamp DNA
Blood Mini Kit (QIAGEN, Hilden, Germany) following the
manufacturer’s instructions. The Tanzanian sample was collected
from a patient in Nyamisati village diagnosed by microscopy with
P. vivax and was part of a longitudinal study granted ethical
approval from the National Institute for Medical Research, Dar es
Salaam, Tanzania. DNA extraction was performed using a
QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany)
following the manufacturer’s instructions.
For all samples, written informed consent was obtained from the
sample donors, with the exception of the Japanese traveller’s
samples collected at the International Medical Centre Hospital,
Tokyo, which does not require written informed consent for the
use of parasite DNA from patients.
Mitochondrial genome sequencing
The entire ,6 kb mitochondrial genome was sequenced from
single P. vivax samples from Rwanda, Sa˜o Tome´, Angola,
Tanzania and Niger, 18 samples from Madagascar (yielding 25
individual mitochondrial genomes), and 10 samples from Turkey.
The mitochondrial genomic DNA was amplified by PCR, with the
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entire genome being amplified in two separate reactions. 1 mL of
extracted DNA solution was added to 25 mL of distilled H20,
1.75 mL of each primer (5 mM, see Table S1 for primer
sequences), 5 mL of 10X LA PCRTM Buffer II, 5 mL of 25 mM
MgCl2 solution, 8 mL of dNTP mixture (2.5 mM each) and 0.5 mL
of TaKaRa LA TaqTM (TaKaRa Bio Inc., Japan) in a 50 mL
reaction. The following cycling conditions were applied using a
GeneAmpH PCR 9700 thermocycler (Applied Biosystems, USA):
94uC for 1 minute, 40 cycles of 94uC for 20 seconds, 58uC for
30 seconds, 72uC for 4 minutes and a final extension step of 72uC
for 10 minutes. PCR products were visualised on 1% agarose gels,
and purified using QIAquickH PCR purification kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instructions,
prior to sequencing. Sequencing reactions were carried out in a
5 mL reaction consisting of 1 mL of purified PCR product (at a
concentration of 10 fmol/mL), 1 mL of sequencing primer (Table
S1), 0.5 mL of distilled H20, 1 mL of BigDyeH Terminator v3.1
Cycle Sequencing mixture and 0.5 mL of BigDyeH Sequencing
Buffer (Applied Biosystems, USA). Cycle conditions were; 96uC for
1 minute, 25 cycles of 96uC for 30 seconds, 50uC for 30 seconds
and 60uC for 4 minutes. Sequencing reaction products were
purified using DyeExTM spin protocol for dye-terminator removal
(QIAGEN, USA), according to the manufacturer’s instructions.
Purified products were sequenced on a 3100 Genetic Analyzer
(Applied Biosystems, USA), and contiguous sequences were
constructed using ATGC version 4.01 (Genetyx Corporation,
USA). PCR products were sequenced in both directions, and the
entire sequencing process was carried out twice for each isolate
including the initial PCR. Singleton mutations were verified by a
third round of sequencing of independent PCR products. All
sequences were deposited in GeNbank, accession numbers
JN788737-JN788776. A multi-‘‘T’’ repeat microsatellite marker
spanning nucleotide positions 2734-2747 was removed from all
sequences prior to further analysis.
Calculation of haplotype diversity
The haplotype diversity index (h) for the six geographical sub-
divisions considered here (Melanesia, East Asia, the Indian sub-
continent, Africa, the Middle East and South America) was
calculated using the formula h = {n/(n21)} {12Spi
2} [15] where
pi is the frequency of the i
th mitochondrial genome haplotype and
n is the number of individuals sampled. The variance of h was
calculated using the formula V = {2/n(n21)}[2(n22){S pi
32(S-
pi
2)2}+Spi22(Spi2)2] [16].
Calculation of nucleotide diversity
Nucleotide diversity (p), the average number of nucleotide
differences per site, was determined for each geographical region
using the Jukes and Cantor model implemented in the DnaSP
v5.10 computer software [17].
Haplotype network construction
The 40 newly determined sequences from continental Africa,
Madagascar and Turkey were used to construct a haplotype
network using the NETWORK 4.5.0 programme (Fluxus
technology Ltd. 2006). Additionally, 320 sequences were used to
construct a larger haplotype network in the same way. Isolates
were assigned to geographic populations based on the regions
proposed by Mu and colleagues [12] (Melanesia, East Asia, the
Indian sub-continent, Africa and South America), with the
addition of a new population from the ‘‘Middle East’’ (incorpo-
rating samples from Iran and Turkey). Out-group probabilities
were generated using TCS 1.21 [18,19], and give an estimate of
the relative age of each haplotype, based on their frequencies and
the number of connections to other haplotypes within the network.
Results
Origin of the present day African P. vivax populations
Nine distinct mitochondrial genome haplotypes were present in
samples from Turkey, sub-Saharan Africa and Madagascar, as
shown in Table 1. Haplotype and nucleotide diversities of
worldwide P. vivax populations are shown in Table 2, and give an
estimate for the genetic polymorphism of the mitochondrial
genome among samples from the six geographical locations
considered. East Asia and Melanesia show the highest diversity, in
accordance with previous analyses, which could reflect these
parasite populations being the most ancient [10,12]. Isolates from
the Turkey and Iran and those from the Indian sub-continent have
comparable haplotype diversities (Turkey plus Iran vs. India,
P.0.05), significantly lower than those from East Asia (East Asia
vs. India, P = 0.03; East Asia vs. Turkey plus Iran, P = 0.05), and
lower, but not statistically significantly so, than those from
Melanesia, As expected, diversity was relatively low in South
America (P,0.05 for all comparisons, except with Africa), which is
generally considered to be the location most recently colonised by
P. vivax. Interestingly, however, isolates from Africa have the
lowest haplotype diversity (P,0.05 for all comparisons, except
with South America), which may be indicative of a recent
appearance (or possibly a population bottleneck) of this popula-
tion. In previous analyses [10,12,13], the limited number of
samples from Africa did not allow firm conclusions to be drawn
about the evolutionary history of African P. vivax. Excluding those
samples from northern Africa as well as those of unknown African
origin reveals an even lower haplotype diversity of samples from
sub-Saharan Africa. Overall, these results may reflect a migration
of P. vivax from Asia east into Melanesia, and west into Africa via
the Indian sub-continent.
A haplotype network was constructed using the mitochondrial
genome sequence from the 40 isolates described here (5 from
continental Africa, 10 from Turkey and 25 from Madagascar) and
is shown in Figure 1. The major haplotype found in Madagascar
is also found in Tanzania, Sao Tome´, Niger and Angola. A unique
haplotype was recorded from the Rwandan isolate. There is a very
low haplotype diversity associated with parasites from Madagascar
(h = 0.29), and continental Africa (h = 0.40). The haplotype
diversity of the Turkish samples was much higher (h = 0.80), with
4 unique haplotypes found among the 10 samples sequenced.
Interestingly, haplotypes were not shared between Turkey and
Africa/Madagascar.
These 40 sequences were also combined with 280 previously
published mitochondrial genomes [12,13] in order to construct a
new haplotype network comprised of P. vivax parasites from a
worldwide distribution (Figure 2). There were 117 distinct
haplotypes among the 320 sequences considered, with 99
polymorphic nucleotide positions. The network follows the same
general pattern as previously published trees [10,12], with large
numbers of private haplotypes from East Asia and Melanesia.
There is more haplotype diversity among P. vivax isolates than is
seen with P. falciparum [20], with larger numbers of private
haplotypes in all areas. Although haplotypes segregate according
to geographical location, there are many types that are shared
between locations. There are relatively few private haplotypes
from Africa/Madagascar and South America, which is reflected in
their low haplotype numbers (Table 2). Samples from Turkey
cluster with those from Africa/Madagascar and India, whereas the
two samples reported to be from Iran [13] group with those found
African Human P. vivax
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in Melanesia. The very large number of private haplotypes
originating in East Asia and Melanesia suggests that sampling in
these areas is below that required for saturation, and further
collection from these areas may reveal additional new haplotypes.
Estimates of out-group probabilities (which are indicative of
which haplotypes are most likely to be ancestral, Table S2), reveal
two haplotypes with out-group weights of over 0.08 (marked with
asterisks in Figure 2). The most likely ancestral haplotype from our
analysis (out-group weight, 0.099) is present in India and Melanesia
and South America (where it is the dominant haplotype). The
second most likely ancestral haplotype (out-group weight, 0.086) is
found in Africa/Madagascar, South America, India and Asia.
Discussion
On the origins of extant populations of P. vivax
The haplotype network constructed from the mitochondrial
genome of worldwide P. vivax isolates reflects the genetic diversity
of global extant P. vivax populations. While the network reveals a
similar picture to that previously presented by Mu et al [12], and
Cornejo and Escalante [10], inclusion of a further 30 samples from
sub-Saharan Africa and Madagascar has increased the probability
of reaching sampling saturation. This increases our confidence
that the low haplotype diversity seen in the latter population is not
a sampling effect.
The Melanesian and East Asian populations show the greatest
haplotype and nucleotide diversities. This could suggest that these
populations are the most ancient, and that they are ancestral to P.
vivax samples found elsewhere. Indeed, the way in which haplotype
diversity decreases from East Asia to the Indian sub-continent to
Africa/Madagascar is consistent with the westward movement of
present day P. vivax from a population somewhere in East Asia.
Africa/Madagascar has the lowest haplotype diversity among all
worldwide populations, lower even than South America, which is
generally considered to be the last continent to have been
colonised by P. vivax. Thus our results appear to show that the
present day African/Madagascan P. vivax in humans may be
relatively young compared to other populations.
Other possibilities remain, however. Regardless of the geo-
graphic location where P. vivax the species originated, an event that
probably took place many hundreds of thousands of years ago,
numerous complex geographic movements of P. vivax stocks have
almost certainly taken place since. For example there is no obvious
reason why P. vivax should not have been endemic across Africa
prior to the emergence of Duffy negativity in human populations
on this continent less than one hundred thousand years ago [8].
Such a stock of P. vivax would have been driven close to extinction
under the near fixation of the Duffy negative mutation in the
indigenous human host population. Subsequently the parasites
would have been re-introduced into Africa from an external P.
Table 1. Summary of positions of SNPs in mitochondrial sequences from P. vivax isolates from continental Africa, Turkey and
Madagascar.
Nucleotide position Number of isolates
Haplotype 1864 2179 2306 2316 2549 4169 5644 5848 5862 Africa Turkey Madagascar
1 A T A T T T A A G 1 0 0
2 A T A T A T A A A 4 0 21
3 A T A A A T A A A 0 0 2
4 A T A T A A A A A 0 0 1
5 A T A T A T A C A 0 0 1
6 A C T T A T A A A 0 1 0
7 A T A T A T T A A 0 3 0
8 C T A T A T A A A 0 3 0
9 A T T T A T A A A 0 3 0
Total 5 10 25
doi:10.1371/journal.pone.0029137.t001
Table 2. Haplotype and nucleotide diversity of worldwide P. vivax mitochondrial genomes.
Region of Origin Number of Samples Number of Haplotypes
Haplotype Diversity (h)
(standard error)
Nucleotide
Diversity (p)
East Asia 115 52 0.97 (,0.01) 7.561024
Melanesia 72 39 0.94 (,0.01) 6.261024
Indian sub-continent 31 15 0.86 (60.05) 4.461024
Turkey and Iran 12 6 0.86 (60.06) 4.461024
South America 48 9 0.67 (60.07) 2.061024
Africa 42 12 0.53 (60.09) 1.861024
Sub-Saharan Africa1 35 7 0.36 (60.10) 1.461024
1Excluding those samples from Northern Africa, or of unknown African origin.
doi:10.1371/journal.pone.0029137.t002
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vivax stock when human migration patterns became favourable to
the reintroduction of both the Duffy positive trait and of P. vivax
itself.
One way in which this could have happened is via the import of
East Asian/Indian P. vivax to the coastal areas of east Africa by
early sea-going traders, in much the same way as it is thought that
P. falciparum was introduced to South America [21]. The fact that
the same parasite mitochondrial haplotypes are seen in India and
in east Africa and Madagascar, but that haplotype diversity is
greater in India is consistent with this idea. The absence of shared
haplotypes between the Middle East and Africa, is also consistent
with a re-introduction of P. vivax via a sea route across the Indian
Ocean and not by land through the Middle East.
Several aspects of the haplotype network warrant further
discussion. First, the out-group probability analysis identified the
haplotype most commonly found in South America, haplotype
number 2 (h2), as the most likely ancestral type. The haplotype
identified as the second most likely ancestral type is that found
most commonly in India and Africa (h40), which differs from h2
by a single nucleotide substitution. The central position of h2
within the network, located intermediate between clusters of
isolates from (on the one side) Melanesia and (on the other side)
East Asia, seems quite anomalous if the South American parasite
population is the most recently derived. We therefore propose an
alternative hypothesis regarding the history of P. vivax that is
consistent with the h2 haplotype being the most ancient.
Under this hypothesis current South American P. vivax is
derived from the now extinct European P. vivax which is itself
Figure 1. Haplotype network constructed using NETWORK
4.5.0, incorporating 40 Plasmodium vivax mitochondrial ge-
nome sequences obtained during this work. Node sizes are
proportional to haplotype frequency, and branch lengths are indicative
of the number of single nucleotide differencesbetween sequences.
Node colours indicate the geographic origin of the isolates and are
coded as follows: red= continental Africa (n = 5) (Tanzania (1), Angola
(1), Niger (1), Rwanda (1), and Sao Tome (1)) yellow=Madagascar (25),
brown=Turkey (10). Haplotype diversities (standard error) are, conti-
nental Africa, 0.40 (0.24); Madagascar, 0.29 (0.08); Turkey 0.80 (0.08).
doi:10.1371/journal.pone.0029137.g001
Figure 2. Haplotype network constructed using NETWORK 4.5.0, incorporating 320 P. vivax mitochondrial genome sequences (280
previously published [12,13], and 40 samples from this work). Node sizes are proportional to haplotype frequency. Node colours indicate the
geographic origin of the isolates and are coded as follows; red =Africa, blue = South America, green=Asia, pink=Melanesia, orange= the Indian sub-
continent, brown=Middle East (Turkey and Iran). Hypothetical intermediates are indicated by small black points. The haplotypes marked with an
asterisk are the two with the highest out-group probabilities (see Table S2). Haplotype diversities for geographical regions are given in Table 2.
doi:10.1371/journal.pone.0029137.g002
African Human P. vivax
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derived from an ancient P. vivax stock, found in its time only in
Africa. From this ancient African stock all extant P. vivax is derived
spreading first to Europe and later to the Indian sub-continent and
on to East Asia; independent lineages spread from Africa to
Melanesia. Subsequent to the dispersion of this P. vivax stock out of
Africa, the Duffy negative condition appeared and spread in the
African human population leading to the near extinction of P. vivax
in humans in Africa itself. In the post-Columbus era the
European/ancient African stock of P. vivax crossed the Atlantic
to the Americas, where it survives to this day only in South
America, P. vivax in Europe and North America having been
driven to extinction by the late 20th century. In this scenario the
greater genetic diversity among P. vivax haplotypes seen in the East
Asian and Melanesian populations may be partly due to the larger
pools of parasites in these regions compared to those in South
America, Africa and the Indian subcontinent where bottlenecking
of P. vivax stocks may have occurred during their introductions.
The paradigm of the absolute dependence of P. vivax on DARC
for red blood cell invasion has recently been challenged by a
number of studies that describe infections in Duffy negative
individuals. In 2006, Ryan and colleagues demonstrated the
presence of P. vivax parasites in mosquitoes living in a region
populated almost exclusively by Duffy negative individuals in
western Kenya, and some evidence for blood-stage parasites in a
number of Duffy negative children from the same region [23]. The
following year, Cavasini and colleagues reported the detection of
P. vivax DNA from Duffy negative individuals in Brazil [22].
Following these observations, a landmark report from Madagascar
was published in 2010, claiming that P. vivax parasites frequently
infected Duffy negative people on that island [24]. This finding
raises two main possibilities; firstly, the P. vivax parasites endemic
to this region may have adapted to become able to invade Duffy
negative red blood cells. This would be a very serious situation,
given the proximity of Madagascar to sub-Saharan Africa, and the
potential of such a parasite to spread within the Duffy negative
populations of that continent. Secondly, the possibility exists that
the ‘‘Duffy negative’’ individuals infected with the parasite may be
of a previously undescribed Duffy phenotype that allows the
invasion of P. vivax parasites, while maintaining some character of
Duffy negativity. Our results show that, at least for those samples
collected from the 7 regions of Madagascar described between
1998 and 2005 and analysed in this study, the vast majority of the
parasites shared identical mitochondrial genome sequences with
parasites also found in continental Africa, suggesting that
movement of parasites between Madagascar and Africa has
occurred previously, although we cannot be sure of the direction of
the transfer.
We have previously shown that despite very high levels of Duffy
negativity in the local human populations, P. vivax does occur in
some regions of West central Africa [14], although it is scarce [25].
How transmission is maintained in regions where 95–100% of the
population are supposedly resistant to P. vivax, may appear to be
enigmatic. However, as we have previously pointed out, at a
sufficiently high vectorial capacity (and in west and central Africa
the vectorial capacities for human malaria are typically amongst
the highest in the world) transmission of a malaria parasite can be
readily sustained where only 1–5% of the human population are
susceptible to it [14]. Altogether, therefore, the evidence supports
the likely presence of P. vivax, albeit at low levels, in humans in
west and central Africa.
Intriguingly, very recent reports show that chimpanzees and
gorillas from several locations across Central Africa harbour
parasites with mitochondrial DNA sequences almost identical to P.
vivax [26,27]. There is, therefore, an animal pool of parasites very
similar, or identical, to P. vivax in the heart of this region from
which P. vivax has, until recently, appeared to be entirely absent.
These observations raise questions concerning the movements of
P. vivax-like parasites through historical and prehistorical times in
Africa. Further samples of P. vivax-like parasites isolated from non-
human primates in Africa could shed light on these questions.
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